Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORPACT-1: Neoadjuvant FOLFIRINOX vs Upfront Surgery in Resectable Pancreatic Head Cancer
2024-517719-65-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of oxaliplatin, irinotecan, fluorouracil and folinic acid in pancreatic head cancer (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Overall survival at 18 months after randomisation. Planned start Nov 2024; status: authorised.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acid
03
Conditions
pancreatic head cancer
Beyond the preview
Go deeper on 2024-517719-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517719-65-00.